

INTESTINAL *IN VITRO* CULTURES AS A VALUABLE TOOL FOR HAZARD ASSESSMENT OF NANOMATERIALS


— Sébastien Cambier

sebastien.cambier@list.lu

LUXEMBOURG
INSTITUTE OF SCIENCE
AND TECHNOLOGY



The digestive track



Mouth +
Oesophagus

1.5 min

Chewing

Stomach

2-6 hour


Chyme
production

Intestine

90 hours


Nutrient
absorption

Key elements of the Intestinal Environment



Joana Costa and Arti Ahluwalia, 2019

Intestinal *in vitro* model: Monoculture



- Standard model for intestinal barrier
- Differentiation into enterocytes


...However...



Caco-2/TC7, epithelial cells

- More cell types present
- Mucus present

Intestinal *in vitro* model: Co-culture



Caco-2/TC7, epithelial cells



HT29, goblet cells-mucus secreting

- More cell types present
- Mucus secretion




Intestinal *in vitro* model: Co-culture



Presence Of The Mucous Layer : HT29-MTX %

Mucus staining

Structure observation



0 %




10 %



100 %

Intestinal *in vitro* model: Co-culture

TEER : Trans Epithelial Electric Resistance






TEER



Real epithelial
barrier


Intestinal *in vitro* model: Co-culture

Assessment of Ag NPs effects : Oxidative stress





Intestinal *in vitro* model: Co-culture

Assessment of Ag NPs effects : inflammatory response



Intestinal *in vitro* model: Co-culture


Detection of Ag NPs : TEM




Intestinal *in vitro* model: Co-culture

Effects Ag NPs : Proteomics

Hierarchical clustering



PCA



Intestinal *in vitro* model: Co-culture

CONCLUSIONS

In vitro assays should be physiologically relevant

- ❖ Coculture to be closer to real condition
- ❖ Mucus reduces the effects of exposure

Ag NPs effects are not only caused by Ag-ions

How do we usually test?

OECD Guidelines for the Testing of Chemicals



- ❖ No OECD guideline for *in vitro* intestinal testing
- ❖ No *in vitro* Digestion OECD guidelines
- ❖ No OECD guidelines for Nanotoxicology

NANO HARMONY


Scientific support for harmonised test guidelines

- **Collaboration with Malta Initiative to join (EU) forces**
- **Nano-specific adaptations of OECD TG/GD**
- **Dedicated regulatory risk research & experimental work**
- **Specific endpoints to be addressed: surface chemistry, solubility, reactivity and dustiness of nanomaterials**


TG for *in vitro* toxicity



European Union's Horizon 2020
research and innovation programme
grant



NanoHarmony structure



NanoHarmony

In Vitro Approach for Intestinal Fate of Orally Ingested NMs

- *What is the status of the task description?*

It is ongoing

- *What are the (associated) partners/subcontractors for the task?*

To achieve the task objectives ISS will rely on the following *associated* partners

Federico BENETTI	EcamRicert	IT	f.benetti@ecamricert.com
Stefania SABELLA	IIT	IT	stefania.sabella@iit.it
Juan RIEGO SINTES, Jessica PONTI	JRC	EU	juan.riego-sintes@ec.europa.eu Jessica.PONTI@ec.europa.eu
Alba HERNANDEZ	Univ. Barcelona	ES	alba.hernandez@uab.cat
Arno GUTLEB (Consortium Partner)	List	LU	arno.gutleb@list.lu

} coordinators

- *What are your plans for workshops/interaction with the other WPs/tasks?*

We have planned a possible international workshop on our task topics and we believe to have fruitful interactions with tasks 2.1, 2.2, 2.5, 2.6, 2.7 and with WP3

- *How is your contact with the national representatives (WPMN head of delegation and WNT national coordinator)?*

Very close, Isabella De Angelis is the Head of Italian delegation at WPMN while the WNT National Coordinator, Gabriele Aquilina, is member of ISS permanent staff

CONCLUSIONS

In vitro assays should be physiologically relevant

- ❖ Coculture to be closer to real condition
- ❖ Mucus reduces the effects of exposure
- ❖ Harmonized by intra/inter laboratory round robin

TG will become available for *in vitro* intestinal effects

Merci villmols

